Меню
Набор скоро начнётся NCT06649604

Reducing Pain From Retinal Laser With Vibrational Stimulation

Без фазы С лечением Pain, Perioperative

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Vibration Anesthesia Device, Panretinal Photocoagulation.
Кому может быть актуально
Состояния в реестре: Pain, Perioperative. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Канада
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Alleviating Panretinal Photocoagulation Associated Ocular Pain With Vibratory Stimulation

Обзор

The goal of this clinical trial is to learn if Vibration Anesthesia Device works to reduce pain during retinal laser for diabetic retinopathy. The main question it aims to answer is: Does the Vibration Anesthesia Device reduces the pain felt by patients during the laser treatment? Researchers will compare the standard method (no vibration device) to the standard method with the Vibration Anesthesia Device to see if the device works to reduce discomfort during treatment. Eligible participants will have both eyes treated as required, one eye with the device and the other one without. Both the side that will be treated with the device in place and the first side to be treated will be decided by random sequence.

Подробное описание

Background:

Panretinal photocoagulation (PRP) is a widely used laser treatment for proliferative diabetic retinopathy (PDR). However, the associated ocular pain can make the procedure uncomfortable, leading to increased treatment visits or missed appointments. This pain is multifactorial and can be exacerbated by factors such as anxiety and hypervigilance. Traditional pain management techniques, such as regional anesthesia, are effective but invasive and carry potential complications. Oral medications have largely proven ineffective in alleviating PRP-related pain.

The Gate-Control Theory of pain posits that non-noxious stimuli can inhibit pain signals by activating A-β fibers, effectively "closing the gate" to pain transmission through A-δ and C fibers. The most relatable example is the mother rubbing a child's knee after an impact injury in the affected region. Transcutaneous electrical nerve stimulation (TENS) which utilizes the Gate-Control Theory of pain, has been shown to reduce ocular pain during PRP. However, its use raises practical concerns, including the need to carefully adjust pulse width, intensity, and frequency for effective pain relief. Additionally, some patients may find the muscular contractions or paresthesia uncomfortable. TENS is also contraindicated in individuals who are pregnant, have epilepsy, or have pacemakers. Vibratory stimulation activates cutaneous mechanoreceptors to reduce pain during intramuscular and subcutaneous injections. This technique is safer and less invasive than TENS and is therefore an ideal candidate for evaluating its effect in pain reduction during PRP. This study has the potential for an innovative concept by utilizing a vibratory device integrated within the PRP machine headrest.

Hypothesis:

Vibratory stimulation is expected to reduce ocular pain during PRP by activating cutaneous mechanoreceptors and inhibiting pain transmission, as suggested by the Gate-Control Theory. Its non-invasive nature makes it a practical alternative to traditional pain management methods, potentially enhancing patient comfort during the procedure.

Objective:

To evaluate the effectiveness of vibratory stimulation in reducing ocular pain during PRP treatments

Method:

Subjects will be recruited at a single tertiary referral center (Alberta Retina Consultants, Edmonton, Alberta). Matriculation will be established upon obtainment of consent, and patients will have the autonomy to withdraw from the study at any stage. The enrollment period will be from October 2024 to March 2025, with a total of 50 patients.

Laser settings will be tailored to each patient based on individual differences in pigmentation and tissue uptake. The threshold for treatment will be determined by observing an opacified photothermic response. For each patient, one eye will be treated without vibratory stimulation, while the contralateral eye will receive stimulation using the Blaine Labs Vibration Anesthesia Device. The assignment of which eye receives which treatment will be randomized using Python programming, ensuring a balanced allocation. To minimize variability, the time taken to perform PRP on both eyes will be kept as equal as possible. A no-treatment zone of 1 clock hour from the horizontal meridian will be maintained to avoid the long ciliary nerves. After treatment, patients will complete a validated survey based on the numeric rating scale (NRS) to assess pain levels for each eye treated.

Вмешательства

  • Устройство Vibration Anesthesia Device
    The intervention arm of this study is distinguished by way of the use of the Vibration Anesthesia Device
  • Процедура Panretinal Photocoagulation
    Laser treatment for diabetic retinopathy done in a standard fashion

Первичные конечные точки

  • Pain Rating Scale [Срок оценки: At time of enrolment]

Критерии участия

Критерии включения

  • Treatment naïve patients
  • Bilateral PRP for proliferative diabetic retinopathy required
  • >500 applications to each eye
  • < 51 applications difference between each eye, in the superior or inferior hemisphere.

Критерии исключения

  • Poor pupil dilation < 5mm
  • Media opacity preventing laser

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Перекрёстный дизайн
Маскирование
Простое слепое
Основная цель
Поддерживающая терапия

Центры проведения

Канада · 1 центр
  • Alberta Retina Consultant — Edmonton

Идентификаторы

NCT: NCT06649604 · Pro00144813

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗